Kura Oncology (NASDAQ:KURA) Price Target Raised to $40.00

Kura Oncology (NASDAQ:KURA) had its price target increased by research analysts at HC Wainwright from $37.00 to $40.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 362.43% from the stock’s previous close.

Other analysts also recently issued reports about the company. Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and reduced their price objective for the company from $26.00 to $19.00 in a research note on Monday, October 14th. Wedbush restated an “outperform” rating and set a $37.00 price target on shares of Kura Oncology in a research note on Monday, November 4th. JMP Securities reiterated a “market outperform” rating and issued a $32.00 price objective on shares of Kura Oncology in a research report on Tuesday, November 19th. Jefferies Financial Group cut their price objective on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Thursday, November 21st. Finally, StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $27.13.

Kura Oncology Stock Down 1.9 %

KURA stock opened at $8.65 on Thursday. The company has a market cap of $672.62 million, a price-to-earnings ratio of -3.67 and a beta of 0.78. The company has a fifty day moving average price of $8.79 and a 200 day moving average price of $15.11. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. Kura Oncology has a 12 month low of $6.98 and a 12 month high of $24.17.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Thursday, November 7th. The company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.01. During the same quarter in the previous year, the firm earned ($0.50) earnings per share. Sell-side analysts expect that Kura Oncology will post -2.44 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares of the company’s stock, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Thomas James Doyle sold 4,949 shares of the business’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now owns 88,193 shares in the company, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 12,255 shares of company stock valued at $100,739. Corporate insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

Hedge funds have recently added to or reduced their stakes in the business. nVerses Capital LLC acquired a new stake in shares of Kura Oncology in the third quarter valued at approximately $25,000. Point72 DIFC Ltd purchased a new stake in Kura Oncology in the 3rd quarter valued at approximately $146,000. E Fund Management Co. Ltd. purchased a new position in Kura Oncology during the fourth quarter worth $90,000. Erste Asset Management GmbH purchased a new position in Kura Oncology during the third quarter worth $215,000. Finally, Bellevue Group AG lifted its position in shares of Kura Oncology by 36.0% in the third quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock valued at $266,000 after acquiring an additional 3,600 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.